The investigators discuss their findings that demonstrate patients with previous radiotherapy experienced significantly longer PFS and OS with pembrolizumab treatment versus those with no previous radiotherapy.
Shawna T. Chan, BA
Advertisement
Articles by Shawna T. Chan, BA
Advertisement
Latest Updated Articles
Synergy of Radiotherapy and Anti-PD-1 Therapy With Pembrolizumab in NSCLC: Is This Perfect Harmony?Published: August 23rd 2017 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
